BACKGROUND: Highly active antiretroviral therapy (HAART) results in partial immune restoration for people with AIDS, but its impact on cancer risk among children is unknown. METHODS: Data from the U.S. HIV/AIDS Cancer Match Study were used to evaluate cancer risk for people diagnosed with AIDS as children (diagnosed with AIDS at ages 0-14 years, during 1980-2007, followed for up to 10 years; N = 5,850). We calculated standardized incidence ratios (SIR) to compare cancer risk to the general population. Poisson regression evaluated changes in cancer incidence between the pre-HAART (1980-1995) and HAART eras (1996-2007). RESULTS: There were 106 cancers observed with significantly elevated risks for the two major AIDS-defining cancers: Kaposi sarcoma [KS; N = 20, SIR = 1,694; 95% confidence interval (CI), 986-2,712 and SIR = 1,146; 95% CI, 236-3,349] during the pre-HAART and HAART eras, respectively, and non-Hodgkin lymphoma (NHL; N = 64, SIR = 338; 95% CI, 242-458 and SIR = 116; 95% CI, 74-175). Incidence of both cancers declined 87% and 60%, respectively, in the HAART era (P < 0.05). Of non-AIDS-defining cancers, leiomyosarcoma risk (N = 9) was elevated during both time periods (SIR = 863; 95% CI, 235-2,211 and SIR = 533; 95% CI, 173-1,243). CONCLUSION: People diagnosed with AIDS during childhood remain at elevated risk for KS, NHL, and leiomyosarcoma in the HAART era. Incidence of KS and NHL declined relative to widespread HAART use, but there was no change in the incidence of other cancers. IMPACT: People diagnosed with AIDS during childhood remain at elevated risk for certain cancers. Continued monitoring is warranted as this immunosuppressed population ages into adulthood where cancer risks generally increase.
BACKGROUND: Highly active antiretroviral therapy (HAART) results in partial immune restoration for people with AIDS, but its impact on cancer risk among children is unknown. METHODS: Data from the U.S. HIV/AIDS Cancer Match Study were used to evaluate cancer risk for people diagnosed with AIDS as children (diagnosed with AIDS at ages 0-14 years, during 1980-2007, followed for up to 10 years; N = 5,850). We calculated standardized incidence ratios (SIR) to compare cancer risk to the general population. Poisson regression evaluated changes in cancer incidence between the pre-HAART (1980-1995) and HAART eras (1996-2007). RESULTS: There were 106 cancers observed with significantly elevated risks for the two major AIDS-defining cancers: Kaposi sarcoma [KS; N = 20, SIR = 1,694; 95% confidence interval (CI), 986-2,712 and SIR = 1,146; 95% CI, 236-3,349] during the pre-HAART and HAART eras, respectively, and non-Hodgkin lymphoma (NHL; N = 64, SIR = 338; 95% CI, 242-458 and SIR = 116; 95% CI, 74-175). Incidence of both cancers declined 87% and 60%, respectively, in the HAART era (P < 0.05). Of non-AIDS-defining cancers, leiomyosarcoma risk (N = 9) was elevated during both time periods (SIR = 863; 95% CI, 235-2,211 and SIR = 533; 95% CI, 173-1,243). CONCLUSION:People diagnosed with AIDS during childhood remain at elevated risk for KS, NHL, and leiomyosarcoma in the HAART era. Incidence of KS and NHL declined relative to widespread HAART use, but there was no change in the incidence of other cancers. IMPACT: People diagnosed with AIDS during childhood remain at elevated risk for certain cancers. Continued monitoring is warranted as this immunosuppressed population ages into adulthood where cancer risks generally increase.
Authors: M L Lindegren; R H Byers; P Thomas; S F Davis; B Caldwell; M Rogers; M Gwinn; J W Ward; P L Fleming Journal: JAMA Date: 1999-08-11 Impact factor: 56.272
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Lesley A Anderson; Yan Li; Barry I Graubard; Denise Whitby; Georgina Mbisa; Sylvia Tan; James J Goedert; Eric A Engels Journal: Pediatr Infect Dis J Date: 2008-07 Impact factor: 2.129
Authors: Eric A Engels; Robert J Biggar; H Irene Hall; Helene Cross; Allison Crutchfield; Jack L Finch; Rebecca Grigg; Tara Hylton; Karen S Pawlish; Timothy S McNeel; James J Goedert Journal: Int J Cancer Date: 2008-07-01 Impact factor: 7.396
Authors: J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar Journal: Lancet Date: 1998-06-20 Impact factor: 79.321
Authors: Henrik Hjalgrim; Johan Askling; Klaus Rostgaard; Stephen Hamilton-Dutoit; Morten Frisch; Jin-Song Zhang; Mette Madsen; Nils Rosdahl; Helle Bossen Konradsen; Hans H Storm; Mads Melbye Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Annie J Sasco; Antoine Jaquet; Emilie Boidin; Didier K Ekouevi; Fabian Thouillot; Thomas Lemabec; Marie-Anna Forstin; Philippe Renaudier; Paul N'dom; Denis Malvy; François Dabis Journal: PLoS One Date: 2010-01-11 Impact factor: 3.240
Authors: Chris A Rees; Elizabeth M Keating; Heather Lukolyo; Heather E Danysh; Michael E Scheurer; Parth S Mehta; Joseph Lubega; Jeremy S Slone Journal: Pediatr Blood Cancer Date: 2016-04-15 Impact factor: 3.167
Authors: Sara I Pai; J Jack Lee; Thomas E Carey; William H Westra; Soldano Ferrone; Charles Moore; Marina B Mosunjac; Dong M Shin; Robert L Ferris Journal: Oral Oncol Date: 2017-12-28 Impact factor: 5.337
Authors: Elizabeth L Yanik; Jodi M Smith; Meredith S Shiels; Christina A Clarke; Charles F Lynch; Amy R Kahn; Lori Koch; Karen S Pawlish; Eric A Engels Journal: Pediatrics Date: 2017-05 Impact factor: 7.124